The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
HER2 is a membrane-bound tyrosine kinase that when amplified contributes significantly to a tumor’s ability to proliferate and survive.
Patients with ulcerative colitis have an increased risk of developing colorectal cancer (CRC), are diagnosed with less advanced CRC, and are at increased risk of death from CRC.
Guidelines indicate that there are a number of treatment options for head and neck cancers.
Patients diagnosed with Crohn disease and colorectal cancer (CRC) have a higher rate of mortality than patients without Crohn disease who are also diagnosed with CRC.
In a Directions in Oncology PharmacyTM Peer Exchange series, experts explained the right time to use bevacizumab, either as a front-line therapy or at the time of disease progression.
In a Directions in Oncology Pharmacy Peer Exchange series, experts discuss the PRIMA trial and the rationale for using PARP inhibitors.
Bhavesh Shah, RPh, BCOP, and Katherine Lin, PharmD, BCOP, provide input on individualizing early treatment for chemotherapy-induced nausea and vomiting.
FDA Grants Breakthrough Therapy Designation for Treatment of Locally Advanced, Metastatic Urothelial Cancer
Enfortumab vedotin-ejfv in combination with the anti-PD1-therapy pembrolizumab for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in the first-line setting.
FDA Grants Priority Review to Atezolizumab as First-Line Monotherapy for Advanced Non-Small Cell Lung Cancer
The FDA has accepted Genentech’s supplemental biologics license application (sBLA) and granted priority review for atezolizumab (Tecentriq) as a first-line monotherapy for some patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC).
Phase 3 Trial Shows Pembrolizumab, Chemotherapy Improve Survival in Metastatic Triple-Negative Breast Cancer
In the pivotal phase 3 KEYNOTE-355 study, pembrolizumab (Keytruda, Merck) combined with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) as a first-line treatment for patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed programmed death-ligand 1 (PD-L1).
The DKFZ discovered traces of a total of 23 different virus types in 356 patients with cancer. The most common drivers of tumor initiation and growth were found, including the genome of Epstein-Barr viruses (EBV) and hepatitis B virus (HBV).
Physicians treating patients with platinum-sensitive ovarian cancer can choose from a range of therapies, including doublet chemotherapy with or without bevacizumab (Avastin) and PARP inhibitors.